PRISM BioLab Co.,LTD, a biotechnology company, discovers and develops small molecule inhibitors of protein-protein interaction targets utilizing proprietary PepMetics technology for treating patients suffering from cancer, autoimmune, fibrosis, and other diseases. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has license agreements with Eisai Co., Ltd. and Ohara Pharmaceuticals Co.,Ltd. for the development of drugs for treating cancer and liver diseases. PRISM BioLab Co.,LTD was founded in 2006 and is based in Fujisawa, Japan.
तुलना करने के लिए मीट्रिक्स | 206A | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध206Aपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −6.9x | −0.6x | |
PEG अनुपात | 0.00 | 0.01 | 0.00 | |
क़ीमत/बुक | 0.0x | 1.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 2.7x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 83.1% | 48.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 5.0% | 7.5% | अनलॉक करें |